About the Company
Hawkeye is focused on the development of population-scale testing technology and protocols for the early detection of cancer, neurodegenerative and inflammatory conditions.
Cancer is a growing problem among non-smokers and younger individuals who are typically excluded from screening guidelines.
The Hawkeye team includes medical professionals with three-decades of success in oncology, and over 15 years in liquid biopsy technology development.
Founded in 2019 and privately held, Hawkeye is based in Los Angeles and Ireland.
Hawkeye leverages the collective knowledge of an expert team of immunologists, medical oncologists, physicists, and biotech professionals. They share the vision that radical improvements in the diagnosis of early stage disease are the key to lower cancer mortality, and that these solutions must be affordable and plug-compatible with the standard of care.
Leadership Team
-
André de Fusco
CEO & Co-founder
-
Paul Dempsey, PhD
CSO & Co-founder
-
Richard Chernicoff
Consulting COO
-
Paul Song, MD
Consulting CMO